| Document |
Document Title |
|
WO/2019/120716A1 |
Suggested are triiterpene-glycoside compounds, which are obtainable by the extraction of Gynostemma pentaphyllum which are useful as a sweetener or sweet taste enhancer in preparations and compositions, especially oral edible compositions.
|
|
WO/2019/021122A2 |
The present invention relates to novel Liver X Receptor (LXR) modulators, their use in diagnostic and therapy, more particularly in the treatment of diseases associated with LXR, such as cancer, inflammation, metabolic and autoimmune dis...
|
|
WO/2019/017722A2 |
The present invention relates to a method for producing a ginsenoside from a Gynostemma pentaphyllum-derived adventitious root. Specifically, the present invention relates to a method for producing a ginsenoside from a Gynostemma pentaph...
|
|
WO/2019/011010A1 |
The present invention relates to the field of medicinal chemistry, and specifically to a sweet potato sitosterol glycoside unsaturated fatty acid, an extract, a preparation method therefor, and an application thereof. Sweet potato sitost...
|
|
WO/2018/220103A1 |
A sweetness modifying composition comprising at least one high-intensity sweetener chosen from steviol glycosides and/or mogrosides and at least one low-potency sweetener chosen from cellobiose, psicose, cyclamate and/or 11-O-mogroside V...
|
|
WO/2018/201516A1 |
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...
|
|
WO/2018/196581A1 |
Disclosed is a dihydroartemisinin-steroid conjugate having the following general formula (I) or a pharmaceutically acceptable salt thereof, wherein the dihydroartemisinin molecule at the position 10 thereof is connected to the parent nuc...
|
|
WO/2018/166029A1 |
Disclosed is a method for separating and purifying mogroside V by means of subcritical hydrolytic adsorption technology. The method desorbs a macroporous adsorption resin enriched with mogroside V under subcritical conditions for water, ...
|
|
WO/2018/135699A1 |
The present invention provides a novel ergostenol glycoside derivative. The ergostenol and the glycoside derivative thereof according to the present invention suppresses the production of chemokines increasing according to the skin infla...
|
|
WO/2018/068021A1 |
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...
|
|
WO/2018/062904A1 |
Disclosed are a composition for production of ginsenoside compound K using a high temperature-β-glycosidase and a high temperature-α-L-arabinofuranosidase, and a method for preparing ginsenoside compound k. The composition for producin...
|
|
WO/2018/028144A1 |
The present application provides a separation and purification method for high-purity mogroside V, comprising the following steps: (1) dissolving and centrifuging: taking a Siraitia grosvenorii crude product, and adding water for dissolv...
|
|
WO/2018/013613A1 |
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...
|
|
WO/2018/002897A1 |
The present invention concerns compounds having formula (I) and compositions thereof with a pharmacologically acceptable excipient and uses thereof as a medicament, in particular for the treatment and/or prevention of a disorder selected...
|
|
WO/2017/211079A1 |
The present application relates to a technique for extracting mogroside V. Provided is a method for extracting high-purity mogroside V from Siraitia grosvenorii. The specific steps comprise: pre-treatment of a raw material, extraction, c...
|
|
WO/2017/199033A1 |
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...
|
|
WO/2017/199039A1 |
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...
|
|
WO/2017/186135A1 |
Disclosed in the present invention are a compound and an application thereof for the treatment of cataracts. The structural formula of the compound is shown in formula I. The compound shown in formula I, a prodrug thereof, or a pharmaceu...
|
|
WO/2017/150723A1 |
Algae that generates a sterol and a sterol production method that uses the algae. According to the present invention, a sterol is produced by culturing algae, such as strain AJ7867 (FERM BP-22304) and strains derived therefrom, that has ...
|
|
WO/2017/111979A1 |
The present application relates to crystalline forms A, D, F, G and I of obeticholic acid. These crystalline forms are useful in the production of Obeticholic acid (in particular its purification), which is a drug useful for the treatmen...
|
|
WO/2017/075257A2 |
Disclosed herein are compounds having structural Formula (I), or salts thereof. These compounds are useful as sweet tasting agents and/or sweetness enhancers. Also disclosed are compositions comprising the present compounds and methods o...
|
|
WO/2017/069565A1 |
The present invention relates to a method for selectively producing ginsenoside Rd, which is originally present in a trace amount in ginseng, from panaxadiol-based saponins in ginseng and, more specifically, to a method capable of obtain...
|
|
WO/2017/069561A1 |
The present invention relates to a method for selectively producing ginsenoside F2, compound Mc, and compound O, which is originally present in ginseng in trace amounts, from saponins of ginseng and, more specifically, to a method capabl...
|
|
WO/2017/069569A1 |
The present invention relates to a method for selectively producing compound K and compound Y, which are originally present in trace amounts in ginseng, from saponins of ginseng and, more specifically, to a method capable of obtaining de...
|
|
WO/2017/057851A1 |
The present invention relates to a ginsenoside fatty acid ester compound, a method for preparing same, and a cosmetic composition comprising same and, more specifically, to a ginsenoside fatty acid ester compound, modified into a fatty a...
|
|
WO/2017/057852A1 |
The present invention relates to a ginsenoside fatty acid ester compound, a method for preparing same, and a cosmetic composition comprising same and, more specifically, to a ginsenoside fatty acid ester compound, modified into a fatty a...
|
|
WO/2017/044659A1 |
The present disclosure is directed to compositions, formulations and methods of use thereof in the treatment and prevention of ocular conditions including cataract and presbyopia.
|
|
WO/2017/023694A1 |
This invention relates the use of Cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neop...
|
|
WO/2017/003124A1 |
The present invention relates to a method for screening a mitochondrial activity enhancer by using gypenoside-treated cells, to a composition, containing the gypenoside, for screening the mitochondrial activity enhancer, and to a kit com...
|
|
WO/2016/164504A1 |
The invention provides bioconjugates of heterocylic compounds such as S-adenosylmethionine and S-adenosylhomocysteine with biotin or digoxigenin. The bioconjugates also include carbon and nitrogen linker moiteies of varying length that a...
|
|
WO/2016/127543A1 |
Provided are a class of sucrose ester-type cationic lipoids and a preparation method therefor. A vector prepared by using the cationic lipoid can be used to deliver a nucleic acid. The sucrose ester-type cationic lipoid is prepared by us...
|
|
WO/2016/107471A1 |
The present invention relates to a chemical and pharmaceutical technology, and in particular to a STAT3 and ERK signal pathway inhibitor and a use thereof. On the one hand, provided is a STAT3 and ERK signal pathway inhibitor. The inhibi...
|
|
WO/2016/095249A1 |
Provided are a 20(R)-ginsenoside Rg3 multiacylated derivative, as represented by the formula (I), and a preparation method and antitumor application of same. R=CH3(CH2)nCO, and n=0 to 5.
|
|
WO/2016/095248A1 |
The present invention provides a 20(R)-ginsenoside Rg3 derivative, as represented by the formula (I), and a preparation method and antitumor application of same. R1=H, R2=CnH2n+1CO or R1=CnH2n+1CO, R2=H or R1=R2=CnH2n+1CO, and n=3 to 30.
|
|
WO/2016/090139A1 |
Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined applicati...
|
|
WO/2016/082789A1 |
Described herein are neuroactive steroids of the Formula (II) : or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and ----- are as defined herein. Such compounds are envisioned, in certain...
|
|
WO/2015/177469A1 |
The present invention relates to chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, the invention enables improvement of muscular quality in sarcopenic mammals ...
|
|
WO/2015/168779A1 |
A method for purifying Mogroside V comprises passing a solution of a pre-prepared Siraitia grosvenori primary extract through a multi-column system including a plurality of columns, in series, packed with a porous adsorbent resin to prov...
|
|
WO/2015/171555A1 |
Disclosed is a steviol glycoside referred to as rebaudioside D2. Rebaudioside D2 has five β-D-glucosyl units connected to the aglycone steviol. Also disclosed are methods for producing rebaudioside D2, a UDP-glycosyltransferase fusion e...
|
|
WO/2015/081778A1 |
The present invention belongs to the field of organic synthesis, relates to a method for synthesizing a saponin, and in particular, to a method for constructing a glycosidic bond in a saponin, and comprises the following steps: directly ...
|
|
WO/2015/082012A1 |
Suggested are triterpene-glycoside compounds, which are obtainable by the extraction of Momordica grosvenorii (Siraitia grosvenori) which are useful as a sweetener or sweetener enhancer in preparations and compositions, especially oral e...
|
|
WO/2015/062556A1 |
Use of a composition comprising plant based saponins for regulating and balancing gut microflora in a subject.
|
|
WO/2014/194068A1 |
Compounds which are glycosylates of an A-ring of a cardiotonic steroid, wherein the steroid is attached to the anomeric position of (a) a monosaccharide comprising a C-4 amino group, or (b) an oligosaccharide are provided.
|
|
WO/2014/189351A2 |
The invention relates to the method for producing the compound 6-0-palmitoyl-3-0-β-P-D-glucopyranosyl-campesterol(6-O-PGC)
with a novel structure and with in vivo anti-inflammatory activity, from plant extracts obtained from in vitro c...
|
|
WO/2014/150127A1 |
Fruit extracts containing mogrol glycosides substituted with five or more sugar residues per molecule such as mogroside V may be treated with acid or enzymes to increase the content of mogrol glycosides such as siamenoside I and mogrosid...
|
|
WO/2014/146089A2 |
Novel mogrosides and methods for heir purification are provided herein. In addition, compositions comprising said novel mogrosides and methods for preparing the same are provided.
|
|
WO/2013/149570A1 |
Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal ...
|
|
WO/2013/149571A1 |
Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.
|
|
WO/2013/143494A1 |
Disclosed is a protopanaxatriol ginsenoside preparation method, comprising the following steps: (a) protecting the hydroxyl of the protopanaxatriol, exposing a 20-position hydroxyl and at least one of 3-position, 6-position and 12-positi...
|
|
WO/2013/100712A1 |
The present invention relates to a novel blocker for vascular leakage. The novel blocker for vascular leakage of the present invention inhibits the apoptosis of endothelial cells, suppresses the formation of actin stress fibers induced b...
|
